

About the Conference:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies.
The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.
Read more...
• Non-hodgkin lymphoma
• Multiple myeloma
• Novel indications of CAR T-cell therapy
• CAR-T vs bispecific antibody in multiple myeloma
• Access to CAR-T and bispecific across the globe
• Mechanism of action and resistance to bispecifics
• Predictors of response and toxicity of CAR and bispecific
• Access issues in CAR T-cell treatment
• 1st line high-risk large B-cell lymphoma
• Real world data for CAR-T and bispecific
• Next Generation of CAR T-cell and bispecific antibody therapy
• Outsmarting the Escape Artist: resistance to CART immunotherapy
The programme will include:
Plenary Sessions - Keynote lectures - Case-based lectures- Interactive Case Presentations - Roundtables
Panel Discussions - Debates - Poster Walks - Meet the Expert Sessions - Voting technology
Ample time for in-depth discussion
![]() |
![]() |
